Is Vertex Stock Outperforming the S&P 500?

Boston-based Vertex Pharmaceuticals Incorporated (VRTX) is a fast-growing pharmaceutical company with a market cap of $122.8 billion. It focuses on discovering, developing, and commercializing small-molecule drugs for serious diseases, with a primary focus on cystic fibrosis (CF). Its lead-marketed products include Trikafta, Symdeko, Orkambi, and Kalydeco. 

Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Vertex fits this criterion perfectly, exceeding the mark. Vertex targets therapeutic areas with high unmet needs and has achieved monopolistic success with its CF franchise has led to consistent revenue and earnings growth. Plus, it is also committed to innovation and is developing treatments for a range of diseases, including sickle cell disease, beta thalassemia, kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.